Joseph A. Boystak, MPH ’77

Joseph A. Boystak, MPH ’77, is CEO of Brightwaters Capital. He is a senior investment banker, venture capitalist, and serial company co-founder in the global health care, life sciences, and technology sectors with over 35 years of experience. He was founding managing partner of Health2047 Capital Partners and founding managing director of Global Life Sciences Investment Banking at Jefferies. As an investment banker, he has executed transactions in every sector of health care/life sciences on a global scale including all forms of equity, convertible and debt securities, mergers and acquisitions, corporate partnering, and strategic advisory.

He served as co-founder, investor, board member, and senior executive of spin out companies from top-tier universities and academic medical centers, including Exosome Diagnostics; Bruin Biometrics; Macro Biologics; PapiVax; GenoSpace; PAIGE.AI; and Balboa Geolocation. He is a named co-inventor on five U.S. and European issued patents for the SEM Scanner an FDA-approved, first-in-class medical device technology.

He currently serves on the following boards: Dr.Evidence (chairman); Balboa Geolocation (chairman/CEO); Omelette LLC; SoCalBio; Terasaki Institute; and the Johns Hopkins Bloomberg School of Public Health.

He is a frequent speaker at leading health care industry and investor conferences and has been a member of the Financial Innovation Lab at the Milken Institute and Faster Cures.

He earned his BA at Boston University, MHS at Johns Hopkins Bloomberg School of Public Health, and completed executive education at the Wharton School. He is a registered representative with FINRA and holds Series 7 and 63 securities licenses.